CSL Stock

CSL Gross Profit

Delisted·Jun 19, 2026

The Gross Profit of CSL (CSL.AX) as of Jul 25, 2026 is 8.08 B USD. In the previous year, Gross Profit was 7.67 B USD — a change of 5.32% (higher).

Gross Profit

8.08 BUSD

YoY

5.32%

Last updated:

Gross Profit of CSL is 2026 8.08 B USD. Gross Profit of CSL was 2025 7.67 B USD. It decreases by 5.32% higher compared to the previous year.

The CSL Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2024
51.83 base
Jan 1, 2025
51.93 base
Jan 1, 2026 (e)
50.48 base
Jan 1, 2027 (e)
48.48 base
Jan 1, 2028 (e)
46.28 base
Jan 1, 2029 (e)
42.25 base
Jan 1, 2030 (e)
38.74 base
Jan 1, 2031 (e)
36.68 base
YEARGROSS MARGIN (%)
2031 est 36.68
2030 est 38.74
2029 est 42.25
2028 est 46.28
2027 est 48.48
2026 est 50.48
2025 51.93
2024 51.83
2023 51.28
2022 54.27
2021 56.68
2020 57.11
2019 55.95
2018 55.38
2017 51.94
2016 50.08
2015 53.70
2014 52.86
2013 53.38
2012 50.39
2011 50.74
2010 52.59
2009 52.21
2008 49.17
2007 47.56
2006 41.39
Access this data via the Eulerpool API

CSL Revenue

CSL Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
14.80 B USD
3.81 B USD
2.64 B USD
Jan 1, 2025
15.56 B USD
4.10 B USD
3.00 B USD
Jan 1, 2026 (e)
16.00 B USD
4.86 B USD
3.40 B USD
Jan 1, 2027 (e)
16.66 B USD
5.12 B USD
3.67 B USD
Jan 1, 2028 (e)
17.46 B USD
5.44 B USD
3.96 B USD
Jan 1, 2029 (e)
19.12 B USD
5.70 B USD
4.41 B USD
Jan 1, 2030 (e)
20.85 B USD
5.94 B USD
4.75 B USD
Jan 1, 2031 (e)
22.03 B USD
0.00 USD
5.07 B USD

CSL Margins

CSL stock margins

The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
51.83 %
25.76 %
17.85 %
Jan 1, 2025
51.93 %
26.38 %
19.30 %
Jan 1, 2026 (e)
51.93 %
30.39 %
21.27 %
Jan 1, 2027 (e)
51.93 %
30.71 %
22.05 %
Jan 1, 2028 (e)
51.93 %
31.16 %
22.69 %
Jan 1, 2029 (e)
51.93 %
29.82 %
23.09 %
Jan 1, 2030 (e)
51.93 %
28.50 %
22.80 %
Jan 1, 2031 (e)
51.93 %
0.00 %
23.01 %

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Gross Profit of CSL is 8.08 B USD in 2026.

Access this data via the Eulerpool API

Income Statement — CSL

All Key Metrics — CSL